EGFR and metastatic colorectal cancer: The role of additional agents, such as anti-EGFR compounds or angiogenesis inhibitors should be defined in the therapeutic strategy of the metastatic colorectal cancers, in combination with oral fluoropyrimmidine containing regimen.